Ribonuclease

Watchmaker Genomics Announces Launch of Cost-effective RNase Inhibitor for Single-cell, Single-nuclei, and Pathogen Detection Applications

Retrieved on: 
Tuesday, April 2, 2024
Medical Supplies, Medical Devices, Health, Genetics, Other Health, Biotechnology, Watchmaker, Marketing, Ribonuclease, RNA, Genomics, Pharmaceutical industry

Watchmaker Genomics, a provider of innovative solutions for molecular analysis, announced the launch of a high-purity RNase Inhibitor that is well-suited for a wide range of applications where maintaining RNA integrity is critical, including single-cell and single-nuclei sequencing, as well as pathogen detection.

Key Points: 
  • Watchmaker Genomics, a provider of innovative solutions for molecular analysis, announced the launch of a high-purity RNase Inhibitor that is well-suited for a wide range of applications where maintaining RNA integrity is critical, including single-cell and single-nuclei sequencing, as well as pathogen detection.
  • “We are pleased to bring our RNase Inhibitor to market,” said Sandra Rowe, Vice President of Marketing at Watchmaker.
  • “We aim to be a partner for our customers and provide high-performing yet cost-effective solutions to allow for higher throughput and increased sensitivity.”
    Key features of Watchmaker’s RNase Inhibitor include:
    The launch of the RNase Inhibitor complements Watchmaker’s Precision Enzymes portfolio, which includes the highly thermostable and inhibitor-tolerant StellarScript HT+ Reverse Transcriptase designed for sensitive pathogen detection assays.

Zymo Research Pioneers a Breakthrough in Large-scale Animal-free RNase A Production

Retrieved on: 
Tuesday, March 5, 2024
Ribonuclease, RNA, Prion, Research, Biotechnology, Virus, Failure, DNA, Risk, Vaccine

This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.

Key Points: 
  • This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.
  • Recognizing these challenges, Zymo Research has developed PureRec RNase A, an animal-free recombinant RNase A.
  • PureRec RNase A was developed and manufactured in Zymo Research's state-of-the-art facility in California, empowered by specialized expertise and advanced fermentation and bioprocessing technologies.
  • For more information or bulk inquiries on Zymo Research's recombinant RNase A, please check out PureRec RNase A .

Zymo Research Pioneers a Breakthrough in Large-scale Animal-free RNase A Production

Retrieved on: 
Tuesday, March 5, 2024
Ribonuclease, RNA, Prion, Research, Biotechnology, Virus, Failure, DNA, Risk, Vaccine

This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.

Key Points: 
  • This breakthrough will enable the widespread use of recombinant RNase A in applications where an animal-free enzyme is preferred.
  • RNase A is a critical enzyme extensively utilized in plasmid and genomic DNA purification processes due to its efficacy in degrading RNA contaminants.
  • Recognizing these challenges, Zymo Research has developed PureRec RNase A, an animal-free recombinant RNase A.
  • For more information or bulk inquiries on Zymo Research's recombinant RNase A, please check out PureRec RNase A .

Resolve Therapeutics Announces Publication of Lupus Clinical Trial Results

Retrieved on: 
Monday, February 12, 2024
Ribonuclease, SLE, RNA, Therapy, Digestion, Patient

MIAMI, Feb. 12, 2024 /PRNewswire/ -- Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, today announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine .

Key Points: 
  • MIAMI, Feb. 12, 2024 /PRNewswire/ -- Resolve Therapeutics, a mid-stage clinical development biotechnology company pioneering first-in-class therapies for autoimmune diseases, today announced the publication of results from its phase 2a clinical trial of RSLV-132 in patients with Systemic Lupus Erythematosus (SLE) in Lupus Science & Medicine .
  • The publication entitled "Evaluation of RNase therapy in systemic lupus erythematosus: a randomized phase 2a clinical trial of RSLV-132" describes a proof-of-concept study in SLE patients with moderate-severe cutaneous disease activity.
  • "We would like to express our deepest gratitude to the patients that participated in the study" commented Dr. James Posada chief executive officer of Resolve Therapeutics.
  • "Mounting evidence substantiates the importance of extracellular RNA as a drug target in autoimmune diseases such as SLE and Sjogren's.

ANGUS LAUNCHES COMMERCIAL PRODUCTION OF HEPES BUFFER

Retrieved on: 
Tuesday, October 25, 2022
ISO, HEPES, ISO 9001:2015, Biotechnology, Cell, Deoxyribonuclease, Immunoprecipitation, Company, ANGUS, Multi, CEO, Buffer, Tris, AMP, INCI, Ribonuclease, TRIS, List of life sciences, Fine chemical

BUFFALO GROVE, Ill., Oct. 25, 2022 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty chemicals for Life Sciences and Industrial markets, today announced the commercial launch of HEPES buffer produced at its Sterlington, Louisiana facility.

Key Points: 
  • BUFFALO GROVE, Ill., Oct. 25, 2022 /PRNewswire/ -- ANGUS Chemical Company ("ANGUS" or "Company"), a leading global manufacturer and marketer of specialty chemicals for Life Sciences and Industrial markets, today announced the commercial launch of HEPES buffer produced at its Sterlington, Louisiana facility.
  • HEPES is multi-purpose biological buffer often used to maintain a physiological pH which provides the ideal environment for cells to grow and thrive.
  • HEPES buffer (INCI: Hydroxyethylpiperazine Ethane Sulfonic Acid) can also be used in combination with other ingredients to support the quality and performance of skincare and cosmetics products.
  • "The expansion into commercial production of HEPES is a natural fit with our strategy to become the world's most transparent and dependable manufacturer of essential upstream and downstream bioprocessing chemistries," said ANGUS President and CEO David Neuberger.

Applied DNA Receives New York State Department of Health Conditional Approval for Linea™ 2.0 COVID-19 Assay as Laboratory Developed Test

Retrieved on: 
Tuesday, January 4, 2022
Biotechnology, Infectious Diseases, Health, Genetics, Pharmaceutical, Twitter, Securities Exchange Act of 1934, DNA, COVID-19, Private Securities Litigation Reform Act, CRISPR, Polymerase chain reaction, LDT, Omicron, CDC, Cancer, Applied DNA Sciences, FDA, Laboratory developed test, Cannabis, PCR, RNA, COVID-19 testing, EUA, TCR, Company, Severe acute respiratory syndrome coronavirus 2, Contract, NASDAQ, New York State Department of Health, NYSDOH, Emergency, SEC, CEO, Annual report, CMS, Forward-looking statement, Textile, Research, Drug Quality and Security Act, OSHA, Russell, Infection, Review, Intention, History, LinkedIn, Ribonuclease, Securities Act of 1933, Pharmaceutical industry, Vaccine, Applied Food Technologies

With the conditional approval, ADCL can immediately employ the Linea 2.0 Assay for COVID-19 testing to support New York State-based safeCircle clients for the diagnostic testing of COVID-19.

Key Points: 
  • With the conditional approval, ADCL can immediately employ the Linea 2.0 Assay for COVID-19 testing to support New York State-based safeCircle clients for the diagnostic testing of COVID-19.
  • The Linea 2.0 Assay is conditionally approved for individual and pooled (up to 5-samples) testing.
  • The Linea 2.0 Assay was designed as an evolution of the Companys Linea 1.0 COVID-19 Assay (the Linea 1.0 Assay), which powered safeCircle testing prior to the onset of the Omicron variant.
  • Applied DNA is commercializing LinearDNA, its proprietary, large-scale polymerase chain reaction (PCR)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

RNAi Technologies, Companies & Markets, 2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 4, 2021
Health, Genetics, Safety, MicroRNA, RNA interference, Endoribonuclease-prepared siRNA, Degenerative disease, Cancer, Sirna, Tissue, Culture, RNA transfection, Method, Electroporation, Ribonuclease, RNA, Gene, Lists of diseases, Research, Transfection, Gene expression, Table, Gene silencing, Blood, Animal, Company, Argonaute, Genome, Therapy, Publication, Drug discovery, DNA, Bibliography, Cell, Oligonucleotide, Vaccine

The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development.

Key Points: 
  • The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development.
  • Profiles of 168 companies involved in developing RNAi technologies are presented along with 231 collaborations.
  • They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery.
  • RNAi microarray has been devised and can be tailored to meet the needs for high throughput screens for identifying appropriate RNAi probes.

Global RNA Analysis Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 21, 2021
Biotechnology, Genetics, Health, Death, Agilent Technologies, Genomics, PCR, Genome, Gene, Industry, MicroRNA, Life Technologies Corp. v. Promega Corp., Enzyme, Illumina, Inc., RNA interference, Real-time polymerase chain reaction, Drug discovery, Transcriptome, Merck, Bio-Rad Laboratories, Eurofins Scientific, RNA, Thermo Fisher Scientific, Roche, RT, Merck Group, Mindful Scientific Inc., Forensic pathology, Danaher, Collection, Protein, Company, Danaher Corporation, COVID-19, Ribonuclease, Qiagen, Polymerase chain reaction, CD Genomics, DNA, Vaccine, 3D printing

The "Global RNA Analysis Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global RNA Analysis Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • RNA species (messenger RNA, transfer RNA, and ribosomal RNA) play an important role in the translation of genetic information from DNA to proteins.
  • This report explores the present and future market values of the RNA analysis market, particularly by type of analysis such as microarrays, polymerase chain reaction (PCR), sequencing technologies, and RNAi gene silencing.
  • Also included in the report is a discussion of the impact of COVID-19 on the market and profiles of leading companies in the RNA analysis market.

Thermo Fisher Scientific Announces CE-IVD Mark for Next-Generation TaqPath COVID-19 RNase P 2.0 Assay Kit

Retrieved on: 
Thursday, September 16, 2021
Ribonuclease, Science, Ribonuclease P, Mindful Scientific Inc., Genetic testing, Invitrogen, Pharmaceutical Services Negotiating Committee, Gene, Laboratory, Thermo Fisher Scientific, Patheon, Severe acute respiratory syndrome coronavirus 2, COVID-19, Fisher Scientific, Applied Biosystems, Infection, Face, Research, Animal, Vaccine

By surveying across multiple genes, the test can net accurate results even as mutations shift the genes they express.

Key Points: 
  • By surveying across multiple genes, the test can net accurate results even as mutations shift the genes they express.
  • The TaqPath COVID-19 RNase P 2.0 kit uses an RNase P control to ensure sample integrity, quality and extraction.
  • The TaqPath COVID-19 RNase P 2.0 kit uses a newly designed assay to assess nasopharyngeal and nasal swab samples to detect active COVID-19 cases.
  • The first-generation test, TaqPath COVID-19 CE-IVD RT PCR Kit, has been available with a CE-IVD mark since March 2020.

DGAP-News: Secarna publishes new scientific insights in Nucleic Acid Therapeutics on fundamental determinants of antisense oligonucleotide activity

Retrieved on: 
Thursday, August 5, 2021
Company, MD, Lists of World Heritage Sites, Chief executive officer, Indoleamine 2,3-dioxygenase, Research, Industry, CSO, Ribonuclease H, ASO, Time, Database, LNA, Asos, Gene, Data, Drug discovery, Complementarity, Gene expression, RNA, Doctor of Philosophy, Therapy, Ribonuclease, Fine chemical, Secarna's proprietary drug discovery platform, LNAplusTM, Secarna Pharmaceuticals GmbH & Co. KG, SECARNA'S PROPRIETARY DRUG DISCOVERY PLATFORM, LNAPLUSTM, SECARNA PHARMACEUTICALS GMBH & CO. KG

The article, "Investigation of the activity of antisense oligonucleotides targeting multiple genes by RNA sequencing" was published in Nucleic Acid Therapeutics was published in Nucleic Acid Therapeutics: https://www.liebertpub.com/doi/10.1089/nat.2020.0932

Key Points: 
  • The article, "Investigation of the activity of antisense oligonucleotides targeting multiple genes by RNA sequencing" was published in Nucleic Acid Therapeutics was published in Nucleic Acid Therapeutics: https://www.liebertpub.com/doi/10.1089/nat.2020.0932
    Standard ASO design is based on the sequence complementarity of the oligo to its target.
  • However, the degree of target knockdown that ASOs can achieve varies strongly between different ASOs having full complementarity to the target.
  • In a first step, Secarna investigated the ASO's effectivity against IDO1.
  • Alexander Gebauer, MD, PhD, CEO and Managing Director of Secarna Pharmaceuticals, added: "At Secarna, we are constantly working on improving our proprietary LNAplusTM ASO therapies platform.